

# P I C H A I R A M A N , P H D

BRYN MAWR, PA 19010  
857-600-6097 | pichai.raman@gmail.com

## P R O F E S S I O N A L S U M M A R Y

Accomplished computational biology leader with over 20 years of experience across Pharma, Biotech, and academia in scalable data analysis, with relevant proficiency in informatics, target discovery, biomarker development, and gene therapy. Proven track record in advancing drug discovery pipelines from concept through development, leveraging deep expertise in statistical modeling, artificial intelligence, and machine learning. Demonstrated success in integrating cutting-edge computational technologies into oncology, CNS, immunology, and complex disease programs to deliver transformative health solutions.

## C A R E E R H I G H L I G H T S

- 15+ years' experience leveraging cloud platforms (AWS, GCP, Azure) to design and deploy scalable genomic workflows across transcriptomics, metabolomics, epigenomics, and other omics data types
- 10+ years building and leading cross-functional high performing teams of up to a dozen individuals in machine learning, computational analysis, and bioinformatics engineering
- Over 50+ publications in high impact factor peer-reviewed journals across Precision Oncology, Bioinformatics, Immunogenomics, and Translational science
- Led target discovery efforts in a multi-institutional collaboration (Pediatric Cancer Dream Team / Stand Up to Cancer), identifying GPC2 as a key neuroblastoma target that advanced to clinical trials.
- Played a key role in the original Cancer Cell Line Encyclopedia (CCLE) project and leveraged the data to identify the target and mechanism of action of Englerin A.
- Contributed to groundbreaking research on mechanisms of resistance to CD19-targeted CAR T-cell therapy, identifying alternative splicing and acquired mutations in CD19 as key factors enabling immune evasion in leukemia.
- Senior author on the development of a robust transcriptome-based classifier for medulloblastoma subtyping, achieving over 97% accuracy across independent datasets and enabling reliable classification of retrospective and prospective RNA-based data.

## S K I L L S

- |  |                                      |                                  |
|--|--------------------------------------|----------------------------------|
| • Genomic and transcriptomic analysis        | • Functional genomics                | • Precision Medicine             |
| • MLOps ( CI/CD, explainability)             | • Mult-omics workflows               | • Clinical Development           |
| • AI/ML (TensorFlow, PyTorch)                | • Data integration and visualization | • Leading Cross-functional Teams |
| • Target and Biomarker identification        | • Cheminformatics                    | • Stakeholder Management         |
| • Oncology and gene therapy domain expertise | • Knowledge management               | • Translational Informatics      |

## W O R K E X P E R I E N C E

SPARK THERAPEUTICS, Philadelphia, PA

04/2021 – Present

### Director of Computational Biology and Machine Learning

Responsible for leading the computational biology and machine learning team in support of research and technical development projects.

- NGS Product Characterization: Oversaw next-generation sequencing (NGS) automated workflow for the characterization of vectors and plasmids, ensuring drug product quality.
- Computational Biology Support: Provided pivotal support for research initiatives with single-cell and bulk NGS, imaging analysis, and advanced analytical techniques for target identification and candidate selection.
- Machine Learning Capability Development: Led the development and implementation of cutting-edge deep learning and machine learning strategies to optimize upstream and downstream technical development and enhance discovery platforms within the gene therapy landscape.

GLAXOSMITHKLINE, Collegeville, PA

11/2019 – 04/2021

**Oncology Data Strategy and Design Director**

Defined the data strategy and developed workflows and end points to support oncology research and clinical activities and projects while leading a matrixed team across functions to ensure alignment and execution.

- Oncology Workflows: Spearheaded the development of scalable workflows and tools for translational oncology team to enhance biomarker analytics. Championed strategic AI and ML initiatives to streamline oncology drug discovery, integrating cheminformatics and predictive analytics.
- Data Frameworks: Led strategic initiatives to optimize data management and design frameworks, significantly improving the efficiency of oncology research.

CHILDREN'S HOSPITAL OF PHILADELPHIA, Philadelphia, PA

02/2013 – 11/2019

**Bioinformatics Supervisor and Director of Scientific and Analytic Services (09/2016 – 11/2019)**

**Bioinformatics Scientist III (02/2013 – 09/2016)**

Developed and led an interdisciplinary team of bioinformatic analysts, data scientists, and engineers to deliver strategic informatics solutions and support scientific programs and projects in the pediatric cancer space.

- PedcBioPortal: Headed effort to collaborate with MSKCC, DFCI, and Princess Margaret and build a pediatric-focused cBioPortal for use by the pediatric cancer community ([pedcbioportal.org](http://pedcbioportal.org)).
- Cavatica: Worked with Seven Bridges Genomics to develop a cloud platform for genomic analysis and collaboration ([cavatica.org](http://cavatica.org)).
- Kids First: Helped to design and create the Kids First genomic application that houses pediatric cancer and birth defect genomic and phenotypic data ([kidsfirstdrc.org/portal](http://kidsfirstdrc.org/portal)).
- Mechanisms of Compound Sensitivity: Collaborated with various pharmaceutical companies to determine mechanisms of sensitivity to certain cancer therapeutics.
- Target Discovery in Pediatric Cancer: Led target discovery aim in a multi-institution effort (Pediatric Cancer Dream Team / Stand Up to Cancer) dedicated to cancer immunotherapy by building scalable bioinformatics workflows.

NOVARTIS, Cambridge, MA

09/2005 – 02/2013

**Scientific Technical Leader I (02/2012 – 02/2013)**

**Scientist II (04/2010 – 02/2012)**

**Scientist I (04/2008 – 04/2010)**

**Scientific Associate II (09/2005 – 05/2008)**

Led computational biology initiatives to support early discovery and translational research through the integration of high-dimensional data, development of analysis platforms, and collaborative pipeline building. Focused on accelerating target identification, pathway analysis, and compound profiling across diverse therapeutic areas.

- DiseaseExpress: Worked with cross-departmental team to develop expression warehouse for Novartis with over 60K samples.
- GSEA Project: Developed application in Java (J2EE) to store, manage, and share gene sets. In addition, implemented GSEA to use sets in analysis of microarray and other high-throughput data.
- Compound Set Enrichment: Implemented set enrichment type approach (Pipeline Pilot) to aid in reducing FP rate of high-throughput screens. Worked with other internal groups to determine best methods for clustering and grouping of compound data for use with this approach.
- Cancer Cell Line Encyclopedia: Worked as part of a collaborative team (Broad / NIBR) to develop a pipeline (R) to determine markers (genetic lesion / expression) of sensitivity to compounds across a set of cell lines.
- Expression Signature Project: Spearheaded initiative to create gene expression signatures (R/Bioconductor) to determine pathway activity for use in patient stratification and compound MoA determination.
- mTORC1 Project: Worked with Manning Lab (HMS) to determine specific set of TSC regulated genes from microarray data and associated processes (Metacore). Analysis used to help elucidate biology around mTOR Complex 1.
- Early Target Discovery: Integrated various data types, including copy number data, shRNA / siRNA data, expression data, and mutation data from both tissue and cell line data and developed analysis file in Spotfire DXP for early target discovery purposes. Data sources included internal and public repositories such as the TCGA, GEO, and ArrayExpress. Metacore and IPA used additionally to determine relevant disease pathway links and connections to known oncogenes or disease markers.
- Proteomics: Worked with iTRAQ data across cell lines and compared to mRNA for target / model nomination. Analysis

displayed and reported out to interested parties in Spotfire DXP.

- Education: Developed program alongside education office and quantitative biology unit to educate wet bench biologists on analysis of certain common types of data as well as use of Spotfire DXP.

## EDUCATION

**Doctor of Philosophy (PhD)**, Biomedical Engineering, Science and Health Systems, DREXEL UNIVERSITY, Philadelphia, PA (2016)

**Master of Science (MS)**, Bioinformatics, OHIO STATE UNIVERSITY, Columbus, OH (2005)

**Bachelor of Science (BS)**, Cell and Molecular Biology, UNIVERSITY OF MICHIGAN, Ann Arbor, MI

## PUBLICATIONS

**53 Total Publications | 5 First Author | 4 Second Author | 1 Last Author**

**Selected Publications Listed Below – Full list available at <https://pichairaman.github.io/>**

1. Nabbi A, Beck P, Delaidelli A, Oldridge DA, Sudhaman S, Zhu K, Yang SYC, Mulder DT, Bruce JP, Paulson JN, **Raman P**, Zhu Y, Resnick AC, Sorensen PH, Sill M, Brabetz S, Lambo S, Malkin D, Johann PD, Kool M, Jones DTW, Pfister SM, Jäger N, Pugh TJ. Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours. *Genome Medicine*, 15(1). doi:10.1186/s13073-023-01219-x (2023). PMID: 37679810
2. Shapiro JA, Gaonkar KS, Spielman SJ, Savonen CL, Bethell CJ, Jin R, Rath KS, Zhu Y, Egolf LE, Farrow BK, Miller DP, Yang Y, Koganti T, Noureen N, Koptyra MP, Duong N, Santi M, Kim J, Robins S, Storm PB, Mack SC, Lilly JV, Xie HM, Jain P, **Raman P**, Rood BR, Lulla RR, Nazarian J, Kraya AA, Vaksman Z, Heath AP, Kline C, Scolaro L, Viaene AN, Huang X, Way GP, Foltz SM, Zhang B, Poetsch AR, Mueller S, Ennis BM, Prados M, Diskin SJ, Zheng S, Guo Y, Kannan S, Waanders AJ, Margol AS, Kim MC, Hanson D, Van Kuren N, Wong J, Kaufman RS, Coleman N, Blackden C, Cole KA, Mason JL, Madsen PJ, Koschmann CJ, Stewart DR, Wafula E, Brown MA, Resnick AC, Greene CS, Rokita JL, Taroni JN; Children's Brain Tumor Network; Pacific Pediatric Neuro-Oncology Consortium. OpenPBTA: The Open Pediatric Brain Tumor Atlas. *Cell Genomics*, 3(7):100340. doi: 10.1016/j.xgen.2023.100340. eCollection (2023). PMID: 37492101
3. Dang MT, Gonzalez MV, Gaonkar KS, Rath KS, Young P, Arif S, Zhai L, Alam Z, Devalaraja S, To TKJ, Folkert IW, **Raman P**, Rokita JL, Martinez D, Taroni JN, Shapiro JA, Greene CS, Savonen C, Mafra F, Hakonarson H, Curran T, Haldar M. Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality. *Cell Reports*, 42(6):112600. doi: 10.1016/j.celrep.2023.112600. Epub (2023). PMID: 37235472
4. Maddipati R, Norgard RJ, Baslan T, Rath KS, Zhang A, Saeid A, Higashihara T, Wu F, Kumar A, Annamalai V, Bhattacharya S, **Raman P**, Adkisson CA, Pitarresi JR, Wengyn MD, Yamazoe T, Li J, Balli D, LaRiviere MJ, Ngo TC, Folkert IW, Millstein ID, Bermeo J, Carpenter EL, McAuliffe JC, Oktay MH, Brekken RA, Lowe SW, Iacobuzio-Donahue CA, Notta F, Stanger BZ. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. *Cancer Discovery*, 12(2):542-561. doi: 10.1158/2159-8290.CD-20-1826. Epub (2021). PMID: 34551968
5. Tong CCL, Koptyra M, **Raman P**, Rath KS, Choudhari N, Lin X, Seckar T, Wei Z, Kohanski MA, O'Malley BW, Cohen NA, Kennedy DW, Adappa ND, Robertson ES, Baranov E, Kuan EC, Papagiannopoulos P, Jalaly JB, Feldman MD, Storm PB, Resnick AC, Palmer JN. Targeted gene expression profiling of inverted papilloma and squamous cell carcinoma. *Int Forum Allergy Rhinol*, 12(2), 200-209. doi: 10.1002/alr.22882. Epub (2021). PMID: 34510780
6. Dang MT, Gonzalez MV, Gaonkar KS, Rath KS, Young P, Arif S, Zhai L, Alam Z, Devalaraja S, To TKJ, Folkert IW, **Raman P**, Rokita JL, Martinez D, Taroni JN, Shapiro JA, Greene CS, Savonen C, Mafra F, Hakonarson H, Curran T, Haldar M. Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality. *Cell Rep*, 34(13), 108917. doi: 10.1016/j.celrep (2021). PMID: 33789113
7. Kundra R, Zhang H, Sheridan R, Sirintrapun S, Wang A, Ochoa A, Wilson M, Gross B, Sun Y, Madupuri R, Satravada B, Reales D, Vakiani E, Al-Ahmadie H, Dogan A, Arcila M, Zehir A, Maron S, Berger M, Viaplana C, Janeway K, Ducar M, Sholl L, Dogan S, Bedard P, Surrey L, Sanchez I, Syed A, Rema A, Chakravarty D, Suehnholz S, Nissan M, Iyer G, Murali R, Bouvier N, Soslow R, Hyman D, Younes A, Intlekofer A, Harding J, Carvajal R, Sabbatini P, Abou-Alfa G, Morris L, Janjigian Y, Gallagher M, Soumerai T, Mellinghoff I, Hakimi A, Fury M, Huse J, Bagrodia A, Hameed M, Thomas S, Gardos S, Cerami E, Mazor T, Kumari P, **Raman P**, Shivdasani P, MacFarland S, Newman S, Waanders A, Gao J, Solit DSchultz N. OncoTree: A Cancer Classification System for Precision Oncology. *JCO Clinical Cancer Informatics* 221-230 doi:10.1200/cci.20.0010 (2021). PMID: 33625877

8. Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D, Krek A, Ma W, Zhu Y, Ji J, Calinawan A, Whiteaker J, Colaprico A, Stathias V, Omelchenko T, Song X, **Raman P**, Guo Y, Brown M, Ivey R, Szpyt J, Guha Thakurta S, Gritsenko M, Weitz K, Lopez G, Kalayci S, Gümüş Z, Yoo S, da Veiga Leprevost F, Chang H, Krug K, Katsnelson L, Wang Y, Kennedy J, Voytovich U, Zhao L, Gaonkar K, Ennis B, Zhang B, Baubet V, Tauhid L, Lilly J, Mason J, Farrow B, Young N, Leary S, Moon J, Petyuk V, Nazarian J, Adappa N, Palmer J, Lober R, Rivero-Hinojosa S, Wang L, Wang J, Broberg M, Chu R, Moore R, Monroe M, Zhao R, Smith R, Zhu J, Robles A, Mesri M, Boja E, Hiltke T, Rodriguez H, Zhang B, Schadt E, Mani D, Ding L, Iavarone A, Wiznerowicz M, Schürer S, Chen X, Heath A, Rokita J, Nesvizhskii A, Fenyö D, Rodland K, Liu T, Gygi S, Paulovich A, Resnick A, Storm P, Rood B, Wang P, Francis A, Morgan A, Waanders A, Viaene A, Buccoliero A, Chinnaiyan A, Leonard C, Kline C, Caporalini C, Kinsinger C, Li C, Kram D, Hanson D, Appert E, Kawaler E, Raabe E, Jackson E, Greenfield J, Stone G, Getz G, Grant G, Teo G, Pollack I, Cain J, Foster J, Phillips J, Palma J, Ketchum K, Ruggles K, Blumenberg L, Cornwell M, Sarmady M, Domagalski M, Ciešlik M, Santi M, Li M, Ellis M, Wyczalkowski M, Connors M, Scagnet M, Gupta N, Edwards N, Vitanza N, Vaske O, Becher O, McGarvey P, Firestein R, Mueller S, Winebrake S, Dhanasekaran S, Cai S, Partap S, Patton T, Le T, Lorentzen T, Liu WBocik W. Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. *Cell* 183: 1962-1985.e31 doi:10.1016/j.cell.2020.10.044 (2020). [PMID: 33242424](#)
9. Gaonkar K, Marini F, Rath K, Jain P, Zhu Y, Chimicles N, Brown M, Naqvi A, Zhang B, Storm P, Maris J, **Raman P**, Resnick A, Strauch K, Taroni JRokita J. annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions. *BMC Bioinformatics* 21: doi:10.1186/s12859-020-03922-7 (2020). [PMID: 33317447](#)
10. Rath K, Arif S, Koptyra M, Naqvi A, Taylor D, Storm P, Resnick A, Rokita J, **Raman P** (2020) A transcriptome-based classifier to determine molecular subtypes in medulloblastoma. *PLOS Computational Biology* 16: e1008263 doi:10.1371/journal.pcbi.1008263 (2020). [PMID: 33119584](#)
11. Tetri L, Kolla V, Golden R, Iyer R, Croucher J, Choi J, Macfarland S, Naraparaju K, Guan P, Nguyen F, Gaonkar K, **Raman P**, Brodeur G. RET receptor expression and interaction with TRK receptors in neuroblastomas. *Oncology Reports* doi:10.3892/or.2020.7583 (2020). [PMID: 32319659](#)
12. Rentas S, Rath K, Kaur M, **Raman P**, Krantz I, Sarmady MTayoun A. Diagnosing Cornelia de Lange syndrome and related neurodevelopmental disorders using RNA sequencing. *Genetics in Medicine* 22: 927-936 doi:10.1038/s41436-019-0741-5 (2020). [PMID: 31911672](#)
13. Martin C, Datta A, Littlefield C, Kalra A, Chapron C, Wawersik S, Dagbay K, Brueckner C, Nikiforov A, Danehy F, Streich F, Boston C, Simpson A, Jackson J, Lin S, Danek N, Faucette R, **Raman P**, Capili A, Buckler A, Carven G, Schürpf T. Selective inhibition of TGFβ1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape. *Science Translational Medicine* 12: eaay8456 doi:10.1126/scitranslmed.aay8456 (2020). [PMID: 32213632](#)
14. Sussman R, Rokita J, Huang K, **Raman P**, Rath K, Martinez D, Bosse K, Lane M, Hart L, Bhatti T, Pawel B, Maris J. CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma. *Frontiers in Oncology* 10: doi:10.3389/fonc.2020.00302 (2020). [PMID: 32211329](#)
15. Ijaz H, Koptyra M, Gaonkar K, Rokita J, Baubet V, Tauhid L, Zhu Y, Brown M, Lopez G, Zhang B, Diskin S, Vaksman Z, Mason J, Appert E, Lilly J, Lulla R, De Raedt T, Heath A, Felmeister A, **Raman P**, Nazarian J, Santi M, Storm P, Resnick A, Waanders A, Cole K. Pediatric high-grade glioma resources from the Children's Brain Tumor Tissue Consortium. *Neuro-Oncology* 22: 163-165 doi:10.1093/neuonc/noz192 (2019). [PMID: 32256484](#)
16. MacFarland S, Zelle K, Surrey L, Gallo D, Luo M, **Raman P**, Wertheim G, Hunger S, Li MBrodeur G. Pediatric Somatic Tumor Sequencing Identifies Underlying Cancer Predisposition. *JCO Precision Oncology* 1-26 doi:10.1200/po.19.00062 (2019). [PMID: 32783018](#)
17. Rokita J, Rath K, Cardenas M, Upton K, Jayaseelan J, Cross K, Pfeil J, Egolf L, Way G, Farrel A, Kendersky N, Patel K, Gaonkar K, Modi A, Berko E, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm J, Marshall G, Tyrrell V, Kalletta K, Braun F, Qi L, Du Y, Zhang H, Lindsay H, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan A, Leraas K, Coppens S, Doddapaneni H, Momin Z, Zhang W, Sacks G, Hart L, Krytska K, Mosse Y, Gatto G, Sanchez Y, Greene C, Diskin S, Vaske O, Haussler D, Gastier-Foster J, Kolb E, Gorlick R, Li X, Reynolds C, Kurmasheva R, Houghton P, Smith M, Lock R, **Raman P**, Wheeler DMaris J. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. *Cell Reports* 29: 1675-1689.e9 doi:10.1016/j.celrep.2019.09.071 (2019). [PMID: 31693904](#)
18. **Raman P**, Zimmerman S, Rath K, de Torrenté L, Sarmady M, Wu C, Leipzig J, Taylor D, Tozeren A, Mar J. A comparison of survival analysis methods for cancer gene expression RNA-Sequencing data. *Cancer Genet.* 2019;235-236:1-12. doi:10.1016/j.cancergen.2019.04.004 (2019). [Science Direct: S2210776218304897](#)

19. **Raman P**, Maddipati R, Lim K, Tozeren A. Pancreatic cancer survival analysis defines a signature that predicts outcome. *PLOS ONE*, 13(8):e0201751 (2018). PMID: [30092011](#)
20. Campbell B, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin J, Hodel K, Zahurancik W, Suo Z, Lipman T, Wimmer K, Kratz C, Bowers D, Laetsch T, Dunn G, Johanns T, Grimmer M, Smirnov I, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, **Raman P**, Cole K, Storm P, Yalon M, Opocher E, Mason G, Thomas G, Sabel M, George B, Ziegler D, Lindhorst S, Issai V, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati M, Chung J, Ramaswamy V, Irwin M, Aronson M, Durno C, Taylor M, Rechavi G, Maris J, Bouffet E, Hawkins C, Costello J, Meyn M, Pursell Z, Malkin D, Tabori U, Shlien A. Comprehensive Analysis of Hypermutation in Human Cancer. *Cell*, 171(5):1042-1056.e10 (2017). PMID: [29056344](#)
21. Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor K, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, **Raman P**, Waanders A, Han H, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville H, Bridges L, Martin A, Al-Sarraj S, Chandler C, Ng H, Li X, Mu K, Trabelsi S, Brahim D, Kisljakov A, Konovalov D, Moore A, Carcaboso A, Sunol M, de Torres C, Cruz O, Mora J, Shats L, Stavale J, Bidinotto L, Reis R, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily M, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker S, Pfister S, Jones D, Fouladi M, von Bueren A, Baudis M, Resnick A, Jones C. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. *Cancer Cell*, 32(4):520-537.e5 (2017). PMID: [28966033](#)
22. Bosse K, **Raman P**, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi K, Kendsersky N, Randall M, Donovan L, Morrissy S, Sussman R, Zhelev D, Feng Y, Wang Y, Hwang J, Lopez G, Harenza J, Wei J, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra M, Taylor M, Dimitrov D, Mackall C. and Maris, J. "Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma". *Cancer Cell*, 32(3), pp.295-309.e12 (2017). PMID: [28898695](#)
23. Padovan-Merhar O, **Raman P** (co-first author), Ostrovnya I, Kalletta K, Rubnitz K, Sanford E, Ali S, Miller V, Mossé Y, Granger M, Weiss B, Maris J, Modak S. "Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome." *PLOS Genetics*, 12(12), p.e1006501 (2016). PMID: [27997549](#)
24. Sotillo E, Barrett D, Bagashev A, Black K, Lanauze C, Oldridge D, Sussman R, Harrington C, Chung E, Hofmann T, Maude S, Martinez N, **Raman P**, Ruella M, Allman D, Jacoby E, Fry T, Barash Y, Lynch K, Mackall C, Maris J, Grupp S, Thomas-Tikhonenko A. "Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy" *Cancer Discovery*, 5(12):1282-1295 (2015). PMID: [26516065](#)
25. **Raman P**, Purwin T, Pestell R, Tozeren A. "FXD5 is a Marker for Poor Prognosis and a Potential Driver for Metastasis in Ovarian Carcinomas." *Cancer Informatics*, p.113 (2015). PMID: [26494976](#)
26. Carson C, **Raman P**, Tullai J, Xu L, Henault M, Thomas E, Yeola S, Lao J, McPate M, Verkuyl J, Marsh G, Sarber J, Amaral A, Bailey S, Lubicka D, Pham H, Miranda N, Ding J, Tang H, Ju H, Tranter P, Ji N, Krastel P, Jain R, Schumacher A, Loureiro J, George E, Berellini G, Ross N, Bushell S, Erdemli G, Solomon, J. "Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation." *PLOS ONE*, 10(6), p.e0127498 (2015). PMID: [26098886](#)
27. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, **Raman P**, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA. "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity." *Nature*, 483(7391):603-7 (2012). PMID: [22460905](#)
28. Düvel K, Yecies JL, Menon S, **Raman P** (co-second author), Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM, Clish CB, Murphy LO, Manning BD. "Activation of a metabolic gene regulatory network downstream of mTOR complex 1." *Mol Cell*, 39(2):171-83 (2010). PMID: [20670887](#)
29. Asur S, **Raman P**, Otey ME, Parthasarathy S. "A model-based approach for mining membrane protein crystallization trials." *Bioinformatics*, 22(14):e40-8 (2006) PMID: [16873499](#)
30. **Raman P**, Cherezov V, Caffrey M. "The Membrane Protein Data Bank." *Cell Mol Life Sci*, 63(1):36-51 (2006). PMID: [16314922](#)